Prevalence of high-grade anal dysplasia among women with high-grade lower genital tract dysplasia or cancer: Results of a pilot study.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
05 2019
Historique:
received: 14 12 2018
revised: 20 02 2019
accepted: 23 02 2019
pubmed: 5 3 2019
medline: 6 7 2019
entrez: 5 3 2019
Statut: ppublish

Résumé

To estimate the prevalence of high-grade anal dysplasia in women with high-grade dysplasia or carcinoma of the cervix, vagina or vulva. In this cross-sectional study, participants underwent anal cytology, anal HPV testing with Cervista HPV16/18 and high-resolution anoscopy (HRA). Patients with HSIL (high-grade squamous cell intraepithelial lesion) or greater on anal cytology or anal biopsy were referred to a colorectal surgery specialist for further evaluation. Seventy-five women were enrolled in the study, including 47 with cervical (cervix group), 10 with vaginal (vagina group), 15 with vulvar (vulva group), 1 with cervical and vaginal, and 2 with vulvar and vaginal disease. The median age in the cervix group (40 years (range 26-69)) was substantially younger than in the vagina (60 years (38-69)) and the vulva (59 years (36-75)) groups. Anal HSIL based on composite endpoints of the most severe cytology or histology result was diagnosed in 6 patients (8.0%). Anal cytology revealed HSIL in 2 (2.7%), atypical squamous cells of undetermined significance (ASCUS) in 12 (16.0%), low-grade squamous cell intraepithelial lesion (LSIL) in 2 (2.7%), and was normal in 59 (78.7%) patients. Anal HPV16/18 test was positive in 15 (20.0%), negative in 48 (64.0%) and insufficient in 12 (16.0%) patients. Of the 6 women with high-grade anal dysplasia, three (50%) had a positive anal HPV16/18 test. No case of anal cancer was observed. Our results suggest that the prevalence of anal HSIL is elevated among women with HPV-related lower genital tract dysplasia or cancer. To further support the inclusion of this high-risk group into screening guidelines for anal dysplasia, further studies are necessary to determine what screening strategy is suited to this population.

Identifiants

pubmed: 30827725
pii: S0090-8258(19)30134-9
doi: 10.1016/j.ygyno.2019.02.024
pmc: PMC7104617
mid: NIHMS1575969
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

266-270

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

Neoplasma. 2015;62(2):308-14
pubmed: 25591597
Diagn Cytopathol. 2011 May;39(5):323-7
pubmed: 21488174
Dis Colon Rectum. 2014 Mar;57(3):316-23
pubmed: 24509453
Am J Obstet Gynecol. 2015 Sep;213(3):278-309
pubmed: 25797230
J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S1-S27
pubmed: 23519301
Lancet. 1992 Nov 21;340(8830):1271-3
pubmed: 1359331
Int J Gynecol Pathol. 2013 Jan;32(1):76-115
pubmed: 23202792
Nat Rev Dis Primers. 2016 Dec 01;2:16086
pubmed: 27905473
Obstet Gynecol. 2011 Mar;117(3):643-9
pubmed: 21343768
J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):474-9
pubmed: 19779306
Sex Health. 2012 Dec;9(6):580-6
pubmed: 23380236
Womens Health Issues. 2015 Nov-Dec;25(6):720-6
pubmed: 26253825
Lancet Oncol. 2012 May;13(5):487-500
pubmed: 22445259
Gynecol Oncol. 2016 Jun;141(3):492-496
pubmed: 27095188
J Infect Dis. 2010 May 1;201(9):1331-9
pubmed: 20307204
Gynecol Oncol. 2009 Sep;114(3):399-403
pubmed: 19501896
Curr Opin HIV AIDS. 2017 Jan;12(1):26-30
pubmed: 27828801
Dis Colon Rectum. 2018 Jul;61(7):755-774
pubmed: 29878949
Dis Colon Rectum. 2006 Jan;49(1):36-40
pubmed: 16283561
Obstet Gynecol. 2015 Dec;126(6):1294-300
pubmed: 26551180
Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7
pubmed: 18363070
Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1611-22
pubmed: 18628412
Clin Infect Dis. 2014 Jan;58(1):e1-34
pubmed: 24235263
Diagn Cytopathol. 2015 Apr;43(4):301-6
pubmed: 25352375
Obstet Gynecol. 2010 Sep;116(3):578-82
pubmed: 20733438

Auteurs

Joël Fokom Domgue (J)

The Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Department of Gynecology and Obstetrics, Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Cameroon.

Craig Messick (C)

The Department of Colorectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Andrea Milbourne (A)

The Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Ming Guo (M)

The Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Mila P Salcedo (MP)

The Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Department of Obstetrics & Gynecology, Federal University of Health Sciences/Irmandade Santa Casa de Misericordia, Porto Alegre, Brazil.

Kristina R Dahlstrom (KR)

The Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Elizabeth Y Chiao (EY)

Department of Medicine - Infectious Disease, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.

Ashish A Deshmukh (AA)

Department of Management, Policy and Community Health, UTHealth School of Public Health, Houston, TX, USA.

Erich M Sturgis (EM)

The Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Kathleen M Schmeler (KM)

The Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: kschmele@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH